pSivida Corp – Value Drivers - The Road Forward for pSivida


Follow this company

Companies Mentioned

NASDAQ:PSDV
12/09/2013 [ACCESSWIRE]

pSivida Corp (NASDAQ:PSDV) today published a new blog post on The Chairman's Blog, written by the company's President and CEO, Dr. Paul Ashton. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

Dr. Ashton updates stakeholders on pSivida's product pipeline and its plans to move forward as a Specialty Pharma company. He expresses his optimism for the company's product Medidur for posterior uveitis stating, "Medidur is a sustained release micro-insert that delivers the same drug, fluocinolone acetonide, as the FDA approved Retisert (which we successfully developed with Bausch and Lomb). Retisert was approved by the FDA for uveitis affecting the posterior segment of the eye, the same indication we’ll be seeking for Medidur." Read the full blog post from Dr. Paul Ashton on TheChairmansBlog.com (http://www.thechairmansblog.com/paul-ashton/2013-12/value-drivers-the-road-forward-for-psivida.html).

About pSivida Corp.

pSivida Corp., headquartered in Watertown, MA, develops tiny, sustained release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. pSivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, Durasert™ and BioSilicon™, including Tethadur™. The injectable, sustained release micro-insert ILUVIEN® for the treatment of chronic Diabetic Macular Edema (DME) considered insufficiently responsive to available therapies, licensed to Alimera Sciences, Inc., is marketed in the U.K. and Germany and has also received marketing authorization in Austria, France, Portugal, and Spain and is awaiting authorization in Italy. pSivida has instituted the first of two planned pivotal Phase III clinical trials for Medidur™ for the treatment of posterior uveitis, a chronic back-of-the-eye disease. An investigator-sponsored clinical trial is ongoing for an injectable, bioerodible micro-insert to treat glaucoma and ocular hypertension, a product candidate on which Pfizer Inc. has an option. pSivida's FDA-approved Retisert®, licensed to Bausch & Lomb Incorporated, provides long-term, sustained drug delivery to treat posterior uveitis. www.pSivida.com

About TheChairmansBlog.com

TheChairmansBlog.com is an exclusive, online media publication where publically and privatively held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. In addition to management`s insightful blog posts, TheChairmansBlog.com staff and aggregate partners contribute articles on finance, technology, health, and energy while providing updated market trends, news, and information.www.thechairmansblog.com

COMMENTS

Leave a comment...
 * 

Your Name
 *